# TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

> **NCT07489755** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shenzhen TargetRx Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia - Chronic Phase

## Interventions

- **DRUG:** TGRX-678
- **DRUG:** TKI

## Key facts

- **NCT ID:** NCT07489755
- **Lead sponsor:** Shenzhen TargetRx Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-05-01
- **Final completion:** 2031-05-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489755, "TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07489755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*